{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:22:43Z","timestamp":1792318963684,"version":"4.4.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,11,16]],"date-time":"2010-11-16T00:00:00Z","timestamp":1289865600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1038\/nrneph.2010.154","type":"journal-article","created":{"date-parts":[[2010,11,16]],"date-time":"2010-11-16T12:12:17Z","timestamp":1289909537000},"page":"11-21","source":"Crossref","is-referenced-by-count":137,"title":["Epidemiology of hypertensive kidney disease"],"prefix":"10.1038","volume":"7","author":[{"given":"Suneel","family":"Udani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Lazich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George L.","family":"Bakris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,11,16]]},"reference":[{"key":"BFnrneph2010154_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0140-6736(05)70151-3","volume":"365","author":"PM Kearney","year":"2005","unstructured":"Kearney, P. M. et al. Global burden of hypertension: analysis of worldwide data. Lancet 365, 217\u2013223 (2005).","journal-title":"Lancet"},{"key":"BFnrneph2010154_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/00004872-200401000-00003","volume":"22","author":"PM Kearney","year":"2004","unstructured":"Kearney, P. M., Whelton, M., Reynolds, K., Whelton, P. K. & He, J. Worldwide prevalence of hypertension: a systematic review. J. Hypertens. 22, 11\u201319 (2004).","journal-title":"J. Hypertens."},{"key":"BFnrneph2010154_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1161\/01.HYP.0000252676.46043.18","volume":"49","author":"KL Ong","year":"2007","unstructured":"Ong, K. L., Cheung, B. M. Y., Man, Y. B., Lau, C. P. & Lam, K. S. L. Prevalence, awareness and treatment of hypertension among United States adults 1999\u20132004. Hypertension 49, 69\u201375 (2007).","journal-title":"Hypertension"},{"key":"BFnrneph2010154_CR4","volume-title":"Center for Disease Control and Prevention","author":"CA Schoenborn","year":"2009","unstructured":"Schoenborn, C. A. & Heyman, K. M. Health characteristics of adults aged 55 years and over: United States, 2004\u20132007. National Health Statistics Reports, no. 16. Center for Disease Control and Prevention [online] , (2009)."},{"key":"BFnrneph2010154_CR5","unstructured":"2010 Atlas of chronic kidney disease and end-stage renal disease in the United States. United States Renal Data System [online] , (2010)."},{"key":"BFnrneph2010154_CR6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0140-6736(05)17789-7","volume":"365","author":"A Meguid El Nahas","year":"2005","unstructured":"Meguid El Nahas, A. & Bello, A. K. Chronic kidney disease: the global challenge. Lancet 365, 331\u2013340 (2005).","journal-title":"Lancet"},{"key":"BFnrneph2010154_CR7","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","volume":"360","author":"S Lewington","year":"2002","unstructured":"Lewington, S., Clarke, R., Qizibash, N., Peto, R. & Collins, R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903\u20131913 (2002).","journal-title":"Lancet"},{"key":"BFnrneph2010154_CR8","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/01.HYP.25.4.587","volume":"25","author":"HM Perry","year":"1995","unstructured":"Perry, H. M. et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 25, 587\u2013594 (1995).","journal-title":"Hypertension"},{"key":"BFnrneph2010154_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJM199601043340103","volume":"334","author":"MJ Klag","year":"1996","unstructured":"Klag, M. J. et al. Blood pressure and end-stage renal disease in men. N. Engl. J. Med. 334, 13\u201318 (1996).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2010154_CR10","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1001\/archinte.165.8.923","volume":"165","author":"C Hsu","year":"2005","unstructured":"Hsu, C. et al. Elevated blood pressure and risk for end-stage renal disease in subjects without baseline kidney disease. Arch. Intern. Med. 165, 923\u2013928 (2005).","journal-title":"Arch. Intern. Med."},{"key":"BFnrneph2010154_CR11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/MNH.0b013e3282f88a1f","volume":"17","author":"GS Hill","year":"2008","unstructured":"Hill, G. S. Hypertensive nephrosclerosis. Curr. Opin. Nephrol. Hypertens. 17, 266\u2013270 (2008).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"BFnrneph2010154_CR12","doi-asserted-by":"publisher","first-page":"F1136","DOI":"10.1152\/ajprenal.00401.2003","volume":"286","author":"KA Griffin","year":"2004","unstructured":"Griffin, K. A. et al. Effects of calcium-channel blockers on \u201cdynamic\u201d and \u201csteady-state step autoregulation.\u201d Am. J. Physiol. Renal Physiol. 286, F1136\u2013F1143 (2004).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph2010154_CR13","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/ki.2008.701","volume":"75","author":"BI Freedman","year":"2009","unstructured":"Freedman, B. I. et al. Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int. 75, 736\u2013745 (2009).","journal-title":"Kidney Int."},{"key":"BFnrneph2010154_CR14","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1001\/archinte.168.8.832","volume":"168","author":"LJ Appel","year":"2008","unstructured":"Appel, L. J. et al. Long-term effects of renin\u2013angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch. Intern. Med. 168, 832\u2013839 (2008).","journal-title":"Arch. Intern. Med."},{"key":"BFnrneph2010154_CR15","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMra011078","volume":"346","author":"RJ Johnson","year":"2002","unstructured":"Johnson, R. J., Herrera-Acosta, J., Schreiner, G. F. & Rodriguez-Iturbe, B. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N. Engl. J. Med. 346, 913\u2013923 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2010154_CR16","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1093\/ndt\/15.11.1801","volume":"15","author":"L Zarif","year":"2000","unstructured":"Zarif, L. et al. Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis. Nephrol. Dial. Transplant. 15, 1801\u20131807 (2000).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2010154_CR17","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S0272-6386(12)70275-5","volume":"23","author":"SD Schlessinger","year":"1994","unstructured":"Schlessinger, S. D. et al. Clinical documentation of end-stage renal disease due to hypertension. Am. J. Kidney Dis. 23, 655\u2013660 (1994).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2010154_CR18","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/ki.1997.29","volume":"51","author":"A Fogo","year":"1997","unstructured":"Fogo, A. et al. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. Kidney Int. 51, 244\u2013252 (1997).","journal-title":"Kidney Int."},{"key":"BFnrneph2010154_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ndt\/10.supp6.2","volume":"10","author":"P Zucchelli","year":"1995","unstructured":"Zucchelli, P. & Zuccala, A. Can we accurately diagnose nephrosclerosis? Nephrol. Dial. Transplant. 10 (Suppl. 6), 2\u20135 (1995).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2010154_CR20","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","volume":"288","author":"JT Wright Jr","year":"2002","unstructured":"Wright, J. T. Jr et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288, 2421\u20132431 (2002).","journal-title":"JAMA"},{"key":"BFnrneph2010154_CR21","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1056\/NEJMoa0910975","volume":"363","author":"LJ Appel","year":"2010","unstructured":"Appel, L. J. et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N. Engl. J. Med. 363, 918\u2013929 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2010154_CR22","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.mcna.2009.02.001","volume":"93","author":"N Khosla","year":"2009","unstructured":"Khosla, N., Kalaitzidis, R. & Bakris, G. L. The kidney, hypertension and remaining challenges. Med. Clin. N. Am. 93, 697\u2013715 (2009).","journal-title":"Med. Clin. N. Am."},{"key":"BFnrneph2010154_CR23","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1161\/HYPERTENSIONAHA.110.150722","volume":"55","author":"DC Crews","year":"2010","unstructured":"Crews, D. C. et al. Prevalence of chronic kidney disease in persons with undiagnosed or pre-hypertension in the United States. Hypertension 55, 1102\u20131109 (2010).","journal-title":"Hypertension"},{"key":"BFnrneph2010154_CR24","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1161\/HYPERTENSIONAHA.110.151811","volume":"55","author":"R Agarwal","year":"2010","unstructured":"Agarwal, R. Epidemiology of chronic kidney disease among normotensives: but what is chronic kidney disease? Hypertension 55, 1097\u20131099 (2010).","journal-title":"Hypertension"},{"key":"BFnrneph2010154_CR25","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1159\/000313553","volume":"31","author":"RJ Glassock","year":"2010","unstructured":"Glassock, R. J. Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am. J. Nephrol. 31, 462\u2013465 (2010).","journal-title":"Am. J. Nephrol."},{"key":"BFnrneph2010154_CR26","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1159\/000292500","volume":"31","author":"MR Weir","year":"2010","unstructured":"Weir, M. R. & Bakris, G. L. Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am. J. Nephrol. 31, 469\u2013470 (2010).","journal-title":"Am. J. Nephrol."},{"key":"BFnrneph2010154_CR27","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1159\/000292501","volume":"31","author":"HJ Lambers Heerspink","year":"2010","unstructured":"Lambers Heerspink, H. J. & de Zeeuw, D. Debate: PRO position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am. J. Nephrol. 31, 458\u2013461 (2010).","journal-title":"Am. J. Nephrol."},{"key":"BFnrneph2010154_CR28","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S0140-6736(09)62100-0","volume":"375","author":"GL Bakris","year":"2010","unstructured":"Bakris, G. L. et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high-risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized clinical trial. Lancet 375, 1173\u20131181 (2010).","journal-title":"Lancet"},{"key":"BFnrneph2010154_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1161\/HYPERTENSIONAHA.109.129841","volume":"54","author":"LC Plantinga","year":"2009","unstructured":"Plantinga, L. C. et al. Blood pressure control among persons without and with chronic kidney disease: US trends and risk factors 1999\u20132006. Hypertension 54, 47\u201356 (2009).","journal-title":"Hypertension"},{"issue":"Suppl. 2","key":"BFnrneph2010154_CR30","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1053\/j.ajkd.2007.12.012","volume":"51","author":"MV Rao","year":"2008","unstructured":"Rao, M. V., Qiu, Y., Wang, C. & Bakris, G. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999\u20132004. Am. J. Kidney Dis. 51 (Suppl. 2), S30\u2013S37 (2008).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2010154_CR31","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1046\/j.1365-2710.2001.00363.x","volume":"26","author":"E Vermeire","year":"2001","unstructured":"Vermeire, E., Hearnshaw, H., Van Royen, P. & Denekens, J. Patient adherence to treatment: three decades of research. A comprehensive review. J. Clin. Pharm. Ther. 26, 331\u2013342 (2001).","journal-title":"J. Clin. Pharm. Ther."},{"key":"BFnrneph2010154_CR32","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.amjmed.2007.11.025","volume":"21","author":"PA Sarafidis","year":"2008","unstructured":"Sarafidis, P. A. et al. Hypertension awareness, treatment, and control in chronic kidney disease. Am. J. Med. 21, 332\u2013340 (2008).","journal-title":"Am. J. Med."},{"key":"BFnrneph2010154_CR33","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1053\/j.ajkd.2009.09.014","volume":"55","author":"P Muntner","year":"2010","unstructured":"Muntner, P. et al. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am. J. Kidney Dis. 55, 441\u2013451 (2010).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2010154_CR34","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1056\/NEJMoa0808400","volume":"361","author":"M Mauer","year":"2009","unstructured":"Mauer, M. et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N. Engl. J. Med. 361, 40\u201351 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2010154_CR35","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/clinchem\/48.5.699","volume":"48","author":"OF Laterza","year":"2002","unstructured":"Laterza, O. F., Price, C. P. & Scott, M. G. Cystatin C: an improved estimator of glomerular filtration rate? Clin. Chem. 48, 699\u2013707 (2002).","journal-title":"Clin. Chem."},{"key":"BFnrneph2010154_CR36","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1056\/NEJMoa043161","volume":"352","author":"MG Shilpak","year":"2005","unstructured":"Shilpak, M. G. et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N. Engl. J. Med. 352, 2049\u20132060 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2010154_CR37","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/MNH.0b013e3283319b9d","volume":"18","author":"R Agarwal","year":"2009","unstructured":"Agarwal, R. Home and ambulatory blood pressure monitoring in chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 18, 507\u2013512 (2009).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"BFnrneph2010154_CR38","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMp030057","volume":"348","author":"WB White","year":"2003","unstructured":"White, W. B. Ambulatory blood pressure monitoring in clinical practice. N. Engl. J. Med. 348, 2377\u20132378 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2010154_CR39","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/sj.jhh.1001643","volume":"17","author":"PH Gustavsen","year":"2003","unstructured":"Gustavsen, P. H., Hoegholm, A., Bang, L. E. & Kristensen, K. S. White coat hypertension is a cardiovascular risk factor: a 10-year follow-up study. J. Hum. Hypertens. 17, 811\u2013817 (2003).","journal-title":"J. Hum. Hypertens."},{"key":"BFnrneph2010154_CR40","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1001\/archinte.161.18.2205","volume":"161","author":"G Bobrie","year":"2001","unstructured":"Bobrie, G. et al. Is \u201cisolated home\u201d hypertension as opposed to \u201cisolated office\u201d hypertension a sign of greater cardiovascular risk? Arch. Intern. Med. 161, 2205\u20132211 (2001).","journal-title":"Arch. Intern. Med."},{"key":"BFnrneph2010154_CR41","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/sj.ki.5000081","volume":"69","author":"R Agarwal","year":"2006","unstructured":"Agarwal, R. & Andersen, M. J. Prognostic importance of clinic and home blood pressure recordings in patients with chronic kidney disease. Kidney Int. 69, 406\u2013411 (2006).","journal-title":"Kidney Int."},{"key":"BFnrneph2010154_CR42","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/sj.ki.5000145","volume":"69","author":"R Agarwal","year":"2006","unstructured":"Agarwal, R., Andersen, M. J., Bishu, K. & Saha, C. Home blood pressure monitoring improves the diagnosis of hypertension in hemodialysis patients. Kidney Int. 69, 900\u2013906 (2006).","journal-title":"Kidney Int."},{"key":"BFnrneph2010154_CR43","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000206698","volume":"30","author":"R Agarwal","year":"2009","unstructured":"Agarwal, R. et al. Home blood pressure measurements in for managing hypertension in hemodialysis patients. Am. J. Nephrol. 30, 126\u2013134 (2009).","journal-title":"Am. J. Nephrol."},{"key":"BFnrneph2010154_CR44","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1093\/ndt\/gfp074","volume":"24","author":"R Agarwal","year":"2009","unstructured":"Agarwal, R. & Light, R. P. GFR, proteinuria and circadian blood pressure. Nephrol. Dial. Transplant. 24, 2400\u20132406 (2009).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2010154_CR45","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1161\/CIRCULATIONAHA.106.662254","volume":"115","author":"M Kikuya","year":"2007","unstructured":"Kikuya, M. et al. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Circulation 115, 2145\u20132152 (2007).","journal-title":"Circulation"},{"key":"BFnrneph2010154_CR46","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/ndt\/18.3.563","volume":"18","author":"M Liu","year":"2003","unstructured":"Liu, M. et al. Non-dipping is a potent predictor of cardiovascular mortality and is associated with autonomic dysfunction in haemodialysis patients. Nephrol. Dial. Transplant. 18, 563\u2013569 (2003).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2010154_CR47","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2215\/CJN.07011009","volume":"5","author":"R Agarwal","year":"2010","unstructured":"Agarwal, R. & Light, R. P. The effect of measuring ambulatory blood pressure on nighttime sleep and daytime activity\u2014implications for dipping. Clin. J. Am. Soc. Nephrol. 5, 281\u2013285 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2010154_CR48","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jash.2009.07.001","volume":"3","author":"GL Bakris","year":"2009","unstructured":"Bakris, G. L. Is the blockade of the renin\u2013angiotensin system appropriate for all patients with diabetes? J. Am. Soc. Hypertens. 3, 288\u2013290 (2009).","journal-title":"J. Am. Soc. Hypertens."},{"key":"BFnrneph2010154_CR49","doi-asserted-by":"publisher","first-page":"731","DOI":"10.7326\/0003-4819-150-10-200905190-00014","volume":"150","author":"P Sarafidis","year":"2009","unstructured":"Sarafidis, P. & Bakris, G. L. Does evidence support renin\u2013angiotensin system blocking for slowing nephropathy progression in elderly persons? Ann. Intern. Med. 150, 731\u2013733 (2009).","journal-title":"Ann. Intern. Med."},{"key":"BFnrneph2010154_CR50","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.108.125674","volume":"53","author":"R Agarwal","year":"2009","unstructured":"Agarwal, R., Alborzi, P., Satayan, S. & Light, R. P. Dry weight reduction in hypertensive hemodialysis patients (DRIP): a randomized controlled trial. Hypertension 53, 500\u2013507 (2009).","journal-title":"Hypertension"},{"key":"BFnrneph2010154_CR51","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1046\/j.1523-1755.2003.00273.x","volume":"64","author":"N Vasavada","year":"2003","unstructured":"Vasavada, N. & Agarwal, R. Role of excess volume in the pathophysiology of hypertension in chronic kidney disease. Kidney Int. 64, 1772\u20131779 (2003).","journal-title":"Kidney Int."},{"key":"BFnrneph2010154_CR52","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861\u2013869 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2010154_CR53","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851\u2013860 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2010154_CR54","doi-asserted-by":"crossref","unstructured":"The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349, 1857\u20131863 (1997).","DOI":"10.1016\/S0140-6736(96)11445-8"},{"key":"BFnrneph2010154_CR55","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1001\/archinternmed.2009.284","volume":"169","author":"JM Weinberg","year":"2009","unstructured":"Weinberg, J. M. et al. Risk of hyperkalemia in non-diabetic patients with chronic kidney disease receiving anti-hypertensive therapy. Arch. Intern. Med. 169, 1587\u20131594 (2009).","journal-title":"Arch. Intern. Med."},{"key":"BFnrneph2010154_CR56","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1159\/000237742","volume":"30","author":"N Khosla","year":"2009","unstructured":"Khosla, N., Kalaitzidis, R. & Bakris, G. L. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am. J. Nephrol. 30, 418\u2013424 (2009).","journal-title":"Am. J. Nephrol."},{"key":"BFnrneph2010154_CR57","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1001\/archinte.160.5.685","volume":"160","author":"GL Bakris","year":"2000","unstructured":"Bakris, G. L. & Weir, M. R. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch. Intern. Med. 160, 685\u2013693 (2000).","journal-title":"Arch. Intern. Med."},{"key":"BFnrneph2010154_CR58","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/ki.1997.111","volume":"51","author":"AJ Apperloo","year":"1997","unstructured":"Apperloo, A. J., de Zeeuw, D. & de Jong, P. E. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability in renal function. Kidney Int. 51, 793\u2013797 (1997).","journal-title":"Kidney Int."},{"key":"BFnrneph2010154_CR59","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"AV Chobanian","year":"2003","unstructured":"Chobanian, A. V. et al. The seventh report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289, 2560\u20132572 (2003).","journal-title":"JAMA"},{"key":"BFnrneph2010154_CR60","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1161\/01.HYP.0000075790.33892.AE","volume":"41","author":"C Lenfant","year":"2003","unstructured":"Lenfant, C., Chobanian, A. V., Jones, D. W. & Roccella, E. J. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. Hypertension 41, 1178\u20131179 (2003).","journal-title":"Hypertension"},{"issue":"Suppl. 1","key":"BFnrneph2010154_CR61","first-page":"1","volume":"43","author":"AS Levey","year":"2004","unstructured":"Levey, A. S. et al. K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am. J. Kidney Dis. 43 (Suppl. 1), 1\u2013290 (2004).","journal-title":"Am. J. Kidney Dis."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2010.154.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2010.154","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2010.154.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:33:39Z","timestamp":1684470819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2010.154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,16]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["BFnrneph2010154"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2010.154","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,16]]}}}